Oct 05th 2012 - Edison Investment Research today published a report on Exonhit entitled "Prodromal Attack". In summary, the report says:
The recent failure of two high-profile, late stage clinical candidates for Alzheimer’s disease (AD) has highlighted the need to target future therapeutic interventions earlier in the course of this disease. This strengthens the case for using diagnostic tools such as Exonhit’s AclarusDx, both in trials, and if the products are ultimately successful, in clinical practice. Exonhit’s investment case is largely based on the commercial potential of AclarusDx, its blood-based aid for the diagnosis of AD, although it also has an interest in the Phase II trial stage neuropathic pain programme, EHT/AGN 0001, which is partnered with Allergan and Bristol-Myers Squibb.
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »